Trial intelligence / Profile preview

JS005 in active ankylosing spondylitis (Phase II, China)

CTR20212392Phase 2Completed

Sponsor
Shanghai Junshi Biosciences Co., Ltd.
Start
Sep 2021
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
Countries
1
01

Overview

Phase 2, randomised, double-blind trial in ankylosing spondylitis (AS) comparing JS005 with Placebo (2 arms). Started Sep 2021; status: completed.

02

Drugs

roconkibart
03

Conditions

ankylosing spondylitis (AS)

Beyond the preview

Go deeper on CTR20212392.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20212392.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call